Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. announced the issuance of 134,754 common stock shares following the exercise of share options and vesting of restricted stock units, bringing the total issued stock capital to 105,845,847 shares. This update is relevant for shareholders to adjust their stock capital interest calculations, reflecting MaxCyte’s ongoing commitment to enhancing its market presence in the cell-based therapeutics industry.
More about MaxCyte
MaxCyte, Inc. is a leader in cell engineering, offering platform technologies to facilitate the discovery, development, and commercialization of cell-based therapeutics. With over 25 years of experience, MaxCyte’s ExPERT™ platform supports the growing cell therapy market, providing instruments, processing assemblies, and software protocols to advance next-generation medicines.
YTD Price Performance: 14.81%
Average Trading Volume: 64,644
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £387.1M
For detailed information about MXCT stock, go to TipRanks’ Stock Analysis page.
